44
Participants
Start Date
June 30, 2025
Primary Completion Date
October 31, 2025
Study Completion Date
December 31, 2025
Erythropoietin alfa
"Experimental drug: Nanokine 4000 IU, prefilled syringe, subcutaneous injection Manufactured: Nanogen Biopharmaceutical JSC.~Arm 1 (22 volunteers): Nanokineinjection 4000 IU will be administered subcutaneously on Day 1, and after a 28-day washout period, Eprex® injection 4000 IU will be administered subcutaneously on Day 29."
Erythropoietin alfa
"Comparator drug: Eprex® 4000 IU, prefilled syringe, subcutaneous injection Manufactured: Janssen-Cilag Ltd~Arm 2 (22 volunteers): Eprex® injection 4000 IU will be administered subcutaneously on Day 1, and after a 28-day washout period, Eprex injection 4000 IU will be administered subcutaneously on Day 29.~Total: 44 participants will be recruited in the trial."
Nanogen Pharmaceutical Biotechnology Joint Stock Company
INDUSTRY